A Randomized Phase II Trial of First-Line Metastatic Breast Cancer (MBC) Patients: Sub-Set Analysis of Albumin-Bound Paclitaxel (ab-pac) Given Weekly at 150 mg/m2.

被引：0
|
作者：
Gradishar, W. J. [1 ]
Krasnojon, D. [1 ]
Cheporov, S. [1 ]
Makhson, A. N. [1 ]
Manikhas, G. M. [1 ]
Clawson, A. [1 ]
Bhar, P. [1 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P5-19-13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-19-13
引用
收藏
页数：2
相关论文
共 50 条
  • [31] CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC)
    Mackey, J.
    Hurvitz, S.
    Crown, J.
    Forbes, J.
    Roche, H.
    Pinter, T.
    Eiermann, W.
    Kennedy, M. J.
    Priou, F.
    Provencher, L.
    Adrover, E.
    Pienkowski, T.
    Houe, V
    Rupin, M.
    Martin, M.
    CANCER RESEARCH, 2009, 69 (24) : 497S - 498S
  • [32] An open-label, phase II study of weekly nab-paclitaxel as first-line therapy for patients (pts) with metastatic breast cancer (MBC): Safety update.
    Brezden, C. B.
    Cantin, G.
    Younus, J.
    Panasci, L. C.
    Klimo, P.
    Laing, K. E.
    Raymond, N.
    Lam, W.
    Trudeau, M. E.
    Robidoux, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC)
    Rugo, H. S.
    Campone, M.
    Amadori, D.
    Wardley, A.
    Villa, E.
    Conte, P. F.
    Mudenda, B.
    McHenry, B.
    Pivot, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC)
    Gluck, S.
    Lobo, C.
    Reis, I.
    Lopes, G.
    Carmody, C.
    Tukia, K.
    Hurley, J.
    Seo, P.
    Silva, O.
    Slingerland, J.
    Welsh, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).
    Rugo, Hope S.
    Barry, William Thomas
    Moreno-Aspitia, Alvaro
    Lyss, Alan P.
    Cirrincione, Constance
    Mayer, Erica L.
    Naughton, Michael
    Layman, Rachel M.
    Carey, Lisa A.
    Somer, Robert A.
    Perez, Edith A.
    Hudis, Clifford
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC)
    Seidman, A. D.
    Conlin, A. K.
    Bach, A.
    Brufsky, A. M.
    Saleh, M. N.
    Lake, D.
    Dickler, M. N.
    D'Andrea, G.
    Traina, T. A.
    Hudis, C. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): Final results
    Rugo, H. S.
    Campone, M.
    Amadori, D.
    Wardley, A. M.
    Aldrighetti, D.
    Conte, P. F.
    Liu, D.
    Mudenda, B.
    McHenry, M. B.
    Pivot, X. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer
    Gradishar, W. J.
    Krasnojon, D.
    Cheporov, S.
    Makhson, A.
    Georgy, M.
    Clawson, A.
    Hawkins, M. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 215 - 215
  • [39] Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer
    Infante, Jeffrey R.
    Yardley, Denise A.
    Burris, Howard A., III
    Greco, F. Anthony
    Farley, Cindy P.
    Webb, Charles
    Spigel, David R.
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2009, 9 (01) : 23 - 28
  • [40] Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial
    Lang, I.
    Inbar, M.
    Steger, G.
    Greil, R.
    Zvirbule, Z.
    Beslija, S.
    Kahan, Z.
    Taskova, V.
    Kaufmann, B.
    Zielinski, C. C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 277 - 278
12345